Alnylam Pharmaceuticals, Inc.
ALNY
$219.69
$2.711.25%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.80B | 4.29B | 3.71B | 3.21B | 2.46B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.80B | 4.29B | 3.71B | 3.21B | 2.46B |
| Cost of Revenue | 977.45M | 821.95M | 681.87M | 516.97M | 402.72M |
| Gross Profit | 3.83B | 3.46B | 3.03B | 2.69B | 2.06B |
| SG&A Expenses | 1.32B | 1.29B | 1.21B | 1.18B | 1.08B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.80B | 3.53B | 3.21B | 2.95B | 2.64B |
| Operating Income | 999.78M | 752.14M | 501.58M | 264.70M | -180.19M |
| Income Before Tax | 799.57M | 580.45M | 356.43M | 1.33M | -346.30M |
| Income Tax Expenses | -8.42M | 9.18M | 9.41M | -75.51M | -60.49M |
| Earnings from Continuing Operations | 807.99 | 571.27 | 347.02 | 76.84 | -285.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 807.99M | 571.27M | 347.02M | 76.84M | -285.81M |
| EBIT | 999.78M | 752.14M | 501.58M | 264.70M | -180.19M |
| EBITDA | 1.05B | 806.94M | 557.24M | 321.02M | -123.69M |
| EPS Basic | 6.10 | 4.32 | 2.63 | 0.57 | -2.21 |
| Normalized Basic EPS | 3.77 | 2.74 | 1.69 | 0.18 | -1.66 |
| EPS Diluted | 5.93 | 4.16 | 2.51 | 0.50 | -2.21 |
| Normalized Diluted EPS | 3.63 | 2.63 | 1.62 | 0.12 | -1.66 |
| Average Basic Shares Outstanding | 530.18M | 527.20M | 523.98M | 520.87M | 518.01M |
| Average Diluted Shares Outstanding | 550.14M | 542.48M | 533.93M | 526.77M | 518.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |